Innovative Medicine — Adjustments To Revenue Recognized, Percent
Johnson & Johnson Innovative Medicine — Adjustments To Revenue Recognized, Percent increased by 2.2% to $0.05 in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase in the adjustment percentage suggests higher volatility or greater impact from external factors like currency headwinds or increased rebate pressure, whereas a decrease indicates more stable revenue recognition.
Detailed definition
This metric represents the percentage impact of various adjustments, such as currency fluctuations, rebates, returns, or...
Peer comparison
Similar to 'Revenue Deductions' or 'Net Revenue Bridge' metrics found in other large-cap pharmaceutical companies, which track the difference between gross and net sales.
jnj_segment_innovative_medicine_adjustments_to_revenue_recognized_percentHistorical Data
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | 0 | 0 |
| QoQ Change | — | +2.2% |
| YoY Change | — | +2.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — adjustments to revenue recognized, percent?
- Johnson & Johnson (JNJ) reported innovative medicine — adjustments to revenue recognized, percent of $0.05 in Q1 2026.
- What does innovative medicine — adjustments to revenue recognized, percent mean?
- The percentage impact of accounting adjustments and external factors on the segment's reported revenue.